DTC And The Art Of Selling An Establishment Pricing Plan To A Populist President
Executive Summary
The most surprising proposal coming out the Rose Garden drug pricing event was a call for disclosure of prices in DTC ads. As a policy idea, it may be a dud – but that doesn’t mean it isn’t a critical element of the plan.
You may also be interested in...
DTC Advertising: The 'Kick Me' Sign On Big Pharma’s Backs
Treating mandatory wholesale acquisition cost disclosure in TV ads as a major drug pricing reform is close to ludicrous. But the broad approval of the action is an important sign of the continued public image cost of the ads to the drug companies.
How Drug Promotion Might Change Under Trump's Rx Pricing Plan
DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
The reform 'blueprint' might actually live up to its hype.